MeiraGTx’s industry-leading gene therapy manufacturing facility in Shannon, Ireland formally introduced by Head of Irish Government

MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, unveiled its GMP manufacturing facility in Shannon, Ireland, with the Head of Irish Government, Micheál Martin, in attendance.

The facility, online since earlier this year and stretching over 150,000 square feet, is the first commercial-scale gene therapy manufacturing site in Ireland. The facility is unique in its scale and integrated capabilities. The site contains three facilities, one built to be flexible and scalable for viral vector production for clinical and commercial supply, in addition, a facility to manufacture plasmid DNA – the critical starting material for producing gene therapy products – and thirdly, a Quality Control (QC) hub performing advanced biochemical quality control testing for MeiraGTx clinical and commercial programs.

The formal unveiling marks a critical step in MeiraGTx’s mission to develop and deliver potentially curative treatments for patients living with serious diseases.

Read the full story from MeiraGTx.

Related Content

We make UCL’s research physical and life sciences ideas happen.